SCHEMBL1685444

SCHEMBL1685444

CCCNN(C(C)C)C(C)C

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2381066 0.83 CA1 (0.39) CA1
SCHEMBL818368 0.78 TSHR (0.32)
SCHEMBL13146740 0.78
SCHEMBL28069062 0.74 CA12 (0.33) CA1
SCHEMBL26691415 0.74
SCHEMBL818421 0.70 TSHR (0.30)
SCHEMBL24534165 0.69
SCHEMBL23207675 0.67
SCHEMBL28160861 0.67 ALDH1A1 (0.32)
Isopropyl Alcohol SCHEMBL28211442 0.67 CHRNB2 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117794923-A Benzodioxane compound, and preparation method and application thereof 南京红云生物科技有限公司 2024-03-29 CN claimed
US-20220280530-A1 PREVENTION OR TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE Anhui Newstar Pharmaceutical Development Co., Ltd. (CN) 2022-09-08 US claimed
US-10975092-B2 Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) 2021-04-13 US claimed
WO-2021024141-A1 PREVENTION OR TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE LI XIAOXIANG (CN) 2021-02-11 WO claimed
US-20200115386-A1 PYRIMIDINE SEVEN-MEMBERED-RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF Anhui New Star Pharmaceutical Development Co., Ltd . (CN) 2020-04-16 US claimed
EP-3424929-A1 PYRIMIDINE SEVEN-MEMBERED-RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF Anhui New Star Pharmaceutical Development Co., Ltd (CN) 2019-01-09 EP claimed
EP-1904464-A1 1-CYCLOALKYL-5-IODOTETRAZOLES Lanxess Deutschland GmbH (DE) 2008-04-02 EP claimed
WO-2007025586-A1 1-CYCLOALKYL-5-IODOTETRAZOLES LANXESS DEUTSCHLAND GMBH (DE) 2007-03-08 WO claimed
EP-4306566-B1 CURABLE RESIN COMPOSITION, CURED PRODUCT AND ADHESIVE ADEKA CORP (JP) 2026-05-06 EP disclosed
US-12590178-B2 Curable resin composition and method for suppressing curing shrinkage of curable resin composition ADEKA CORPORATION (JP) 2026-03-31 US disclosed
EP-4306567-B1 CURABLE RESIN COMPOSITION, CURED PRODUCT, AND ADHESIVE ADEKA CORP (JP) 2025-06-04 EP disclosed
US-12269917-B2 Curable resin composition ADEKA CORPORATION (JP) 2025-04-08 US disclosed
US-20250109240-A1 ONE-PACK TYPE EPOXY RESIN COMPOSITION ADEKA CORPORATION (JP) 2025-04-03 US disclosed
WO-2025062839-A1 COMPOUND, EPOXY RESIN, CURABLE COMPOSITION, MATERIAL FOR RECYCLING, CURED ARTICLE, METHOD FOR PRODUCING CURED ARTICLE, METHOD FOR PRODUCING DECOMPOSITION PRODUCT, AND DECOMPOSITION METHOD 株式会社ADEKA 2025-03-27 WO disclosed
EP-1481811-A1 Aqueous white pigment compositions CLARIANT INTERNATIONAL LTD. (CH) 2004-12-01 EP disclosed
US-4988725-A Cardiovascular disorders, antiarrhythmia agents STERLING DRUG INC. (US) 1991-01-29 US disclosed
EP-0388654-A2 Azole-1-alkanamides as antiarrhythmic agents and preparation thereof STERLING DRUG INC. (US) 1990-09-26 EP disclosed
US-4916150-A 1H-pyrazole-1-alkanamines antiarrhythmic compositions and use STERLING DRUG INC. (US) 1990-04-10 US disclosed
US-4870095-A 1H-pyrazole-1-alkanamides, antiarrhythmic compositions and use STERLING DRUG, INC. (US) 1989-09-26 US disclosed
EP-0299407-A1 1H-pyrazole-1-alkanamides and preparation useful as antiarrhythmic agents STERLING DRUG INC. (US) 1989-01-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10975092-B2 Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof MST1, STK11, MSTN CA1 4794/4885
US-20200115386-A1 PYRIMIDINE SEVEN-MEMBERED-RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF MST1, STK11, MSTN CA1 4794/4885
US-20220280530-A1 PREVENTION OR TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE MST1, MSTN, MST1R CA1 3065/4885
US-12590178-B2 Curable resin composition and method for suppressing curing shrinkage of curable resin composition SEM1, RER1, JMJD6 CA1 702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.